الفهرس 
Efficacy and safety of intravenous furosemide for the treatment of transient tachypnea of the newborn
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 126 |  |  |
| | | from | 126 | | |
Abstract
Backround: Postnatal respiratory complications among term infants are common. The most commonly reported cause of neonatal respiratory distress is transient tachypnea of the newborn with estimated incidence of 1% to 2% of all newborns. Objectives: The aim of this study was to examine the efficacy of intravenous furosemide in reducing tachypnea, level, duration of oxygen treatment and hospitalization for neonates with transient tachypnea of the newborn. Methods: It was a case control study considering randomization into the study by computer generated randomization. They were randomly divided into two groups: A.group A: Twenty five neonates received Intravenous furosemide (2mg/Kg) once in addition to oxygen and intravenous fluids. B.group B: Twenty five neonates received only oxygen and intravenous fluids.The response to IV furosemide therapy was evaluated by determining:Respiratory rate Heart rateClinical score of transient tachypnea of the newborn Level of respiratory support Fraction of inspired oxygen, before and at 0.5 h and 1 h and 4 hours after drugs therapy. The duration and level of total respiratory support was assigned along with the duration of hospitalization. Results: The studied neonates were between 35th-39th wks gestation. They were 33(66 %) males and 17(34%) females, with mean gestational age of 37.12 ±1.08 weeks and mean birth weight of 2857.80±1.35. Caesarian section was the mode of delivery of 39(78.0%) neonates. Seven neonates (14%) had history of maternal DM while 4(8.0%) had history of maternal preeclamsia